CareFusion Corp a Delaware corporation was incorporated on January 14, 2009. It is a medical technology company. The Company offers a portfolio of products in the areas of medication management, infection prevention, operating room and procedural effectiveness, and respiratory care. Its primary product brands includes: Alaris intravenous (IV) infusion systems, Pyxis and Rowa automated medication dispensing and supply management systems, AVEA, Vela and LTV Series respiratory ventilators, ChloraPrep skin antiseptic products, MedMined data mining surveillance software and analytics, Vital Signs single-use consumables for respiratory care and anesthesiology, and Jaeger and SensorMedics cardiopulmonary diagnostic equipment. The Company operates in two business segments: Medical Systems and Procedural Solutions. In the Medical Systems segment, the Company develops, manufacture and market capital equipment and related supplies for medication management, which includes our infusion and medication dispensing technologies, supply management, as well as respiratory ventilation and diagnostic technologies. In the Procedural Solutions segment, the Company develops, manufacture and market single-use skin antiseptic and other patient-preparation products, specialty IV infusion valves, administration sets and accessories, IV catheters, IV drug preparation products, reusable surgical instruments, non-dedicated ventilator circuits and other disposables used for providing respiratory therapy, as well as single-use consumables for respiratory care and anesthesiology. The Company's competitors includes Baxter International; B. Braun; Fresenius Kabi; Hospira; Omnicell; McKesson; Dräger; MAQUET, 3M; ICU Medical; Becton, Dickinson; Baxter International; B. Braun; Hospira; Smiths Medical; CR Bard; Integra Life Sciences; and Teleflex. The Company's operations are subject to the Federal Food, Drug and Cosmetic Act (FDC Act), as implemented and enforced by the United States Food and Drug Administration (FDA).